Patents by Inventor Michael Broker

Michael Broker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED VP1-CAPSID PROTEIN OF PARVOVIRUS B19
    Publication number: 20170260239
    Abstract: The inventions relates to a modified VP1-capsid protein of parvovirus B19 having reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SEQ ID NO: 1.
    Type: Application
    Filed: January 18, 2017
    Publication date: September 14, 2017
    Inventors: SUSANNE MODROW, Torsten Lowin, Markus Mobs, Michael Broker
  • Modified VP1-capsid protein of parvovirus B19
    Patent number: 9573979
    Abstract: The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: February 21, 2017
    Inventors: Susanne Modrow, Torsten Lowin, Markus Mobs, Michael Broker
  • Modified Vp1-Capsid Protein Of Parvovirus B19
    Publication number: 20070286870
    Abstract: The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1.
    Type: Application
    Filed: September 23, 2005
    Publication date: December 13, 2007
    Applicant: INTERCELL AG
    Inventors: Susanne Modrow, Torsten Lowin, Markus Mobs, Michael Broker
  • Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof
    Patent number: 6733989
    Abstract: Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof Expression of an SmaI fragment, which is about 1.0 kb in size, on the left-hand end of the HindIII R fragment makes it possible to synthesize, by genetic manipulation, a structural phosphoprotein of HCMV. This phosphoprotein, or immunogenic parts thereof, can be used as diagnostic aid or vaccine.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 11, 2004
    Assignee: Dade Behring Marburg GmbH
    Inventors: Michael Mach, Heidi Meyer, Michael Bröker, Leander Lauffer
  • Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
    Patent number: 6300102
    Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: October 9, 2001
    Assignee: Chiron Behring GmbH & Co.
    Inventors: Bernhard Knapp, Klaus-Dieter Hungerer, Michael Bröker, Bernd-Ulrich von Specht, Horst Domdey
  • Process for the production of proteins
    Patent number: 6284520
    Abstract: The invention pertains to the field of recombinant DNA technology and concerns a method for the production of a protein heterologous to yeast in a homogenous form with the aid of Saccharomyces cerevisiae strain HT393 or a derivative thereof carrying a hybrid vector containing the genes for said protein.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: September 4, 2001
    Assignee: Novartis AG
    Inventors: Bernd Meyhack, Michael Bröker
  • Recombinant proteins with the immunoreactivity of hepatitis B virus e antigen (HBeAg), a process for the preparation thereof and the use thereof in immunoassays and vaccines
    Patent number: 6277631
    Abstract: Recombinant yeast expression vectors with the features indicated in the patent claims are described. These recombinant yeast expression vectors can be used for the preparation of HBeAg in yeast host organisms. Appropriate expression systems, transformed host organisms, diagnostic aids and medicinal agents are additionally described.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: August 21, 2001
    Assignee: Dade Behring Marburg GmbH
    Inventors: Michael Noah, Michael Bröker
  • Process for the production of proteins
    Patent number: 5981227
    Abstract: The invention pertains to the field of recombinant DNA technology and concerns a method for the production of a protein heterologous to yeast in a homogeneous form with the aid of Saccharomyces cerevisiae strain HT393 or a derivative thereof carrying a hybrid vector containing the genes for said protein.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: November 9, 1999
    Assignees: Movartis AG, Behringwerke AG
    Inventors: Bernd Meyhack, Michael Broker
  • Schizosaccharomyces-specific polypeptides
    Patent number: 5980891
    Abstract: The invention relates to novel Schizosaccharomyces-specific proteins and their antibodies. These proteins and antibodies can be used for identifying the yeast genus Schizosaccharomyces.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: November 9, 1999
    Inventors: Michael Broker, Johann Hock
  • Immunogenic hybrid protein OprF-OprI derived from Pseudomonas aeruginosa membrane proteins
    Patent number: 5955090
    Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: September 21, 1999
    Assignee: Chiron Behring GmbH & Co.
    Inventors: Bernhard Knapp, Klaus-Dieter Hungerer, Michael Broker, Bernd-Ulrich von Specht, Horst Domdey
  • Structural phosphoprotein (PP150) of human cytomegalovirus, and the preparation and use thereof
    Patent number: 5846733
    Abstract: The phosphorylated structural protein of molecular weight about 150 kd (pp 150) of human cytomegalovirus (HCMV) is highly immunogenic and is reliably recognised by human antisera. This protein can, after assignment and sequencing of the gene, be prepared, in whole or in immunogenic sections, by gene manipulation. Proteins of this type are suitable as reagents, for example in an ELISA, and as constituents of vaccines.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: December 8, 1998
    Assignee: Behring Diagnositcs GmbH
    Inventors: Gerhard Jahn, Birgit-Christine Scholl, Michael Broker, Michael Mach, Bernhard Fleckenstein, Bernd Traupe
  • Peptide of the structural phosphoprotein (pp 150) of human cytomegalovirus, and DNA encoding said peptide
    Patent number: 5728578
    Abstract: The phosphorylated structural protein of molecular weight about 150 kd (pp 150) of human cytomegalovirus (HCMV) is highly immunogenic and is reliably recognised by human antisera. This protein can, after assignment and sequencing of the gene, be prepared, in whole or in immunogenic sections, by gene manipulation. Proteins of this type are suitable as reagents, for example in an ELISA, and as constituents of vaccines.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: March 17, 1998
    Assignee: Behring Diagnostics GmbH
    Inventors: Gerhard Jahn, Birgit-Christine Scholl, Michael Broker, Michael Mach, Bernhard Fleckenstein, Bernd Traupe
  • Expression vectors for the synthesis of proteins in the fission yeast schizosaccharomyces pombe
    Patent number: 5663061
    Abstract: Particularly suitable expression vectors for the synthesis of proteins in the fission yeast Schizosaccharomyces pombe (S. pombe) are described. These expression vectors are (in addition to other advantageous elements, equipped with a strong homologous promoter and terminator).
    Type: Grant
    Filed: January 12, 1995
    Date of Patent: September 2, 1997
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Michael Broker
  • Method for degrading nucleic acids in waste fermentation solutions with Paecilomyces lilacinus
    Patent number: 5369029
    Abstract: A method for degrading nucleic acids in a waste fermentation solution is disclosed. The method comprises exposing the waste solution to RNases and/or DNases released by autolysis of and/or secreted from Paecilomyces lilaninus which are present in or added to the waste solution. The fermentation of the microorganism occurs under sterile conditions. The microorganism can be transformed with nuclease-encoding genes and added to the waste solution before fermentation. The preferred strain of Paecilomyces lilacinus is DSM 5650.
    Type: Grant
    Filed: April 1, 1993
    Date of Patent: November 29, 1994
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Michael Broker, Mathias Fibi